The top biosimilar policy articles of 2024 highlight advancements that include FDA guidance to simplify biosimilar interchangeability and CMS drug price negotiations under the Inflation Reduction Act, ...

To close out the year, 4 senators came together to introduce a new bipartisan bill to protect biosimilar and generic drug ...

Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf ...

Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf ...

The top 5 biosimilar-related articles of the year highlight a significant shift in the pharmaceutical industry, with ...

The top 5 biosimilar-related articles of the year highlight a significant shift in the pharmaceutical industry, with projections indicating strong uptake in biosimilars at the expense of the ...

Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf ...

The 2024 surge in FDA approvals for aflibercept biosimilars reflects significant progress in offering cost-effective ...

The top 5 rheumatology biosimilar articles of 2024 highlight significant FDA approvals, including high-concentration adalimumab and tocilizumab biosimilars, along with evidence supporting the safety ...

On this episode of Not So Different, we reflect on 2024 and this show in particular, taking audiences back through the most ...